Real-world study demonstrates effectiveness and safety of deucravacitinib in patients with moderate-to-severe plaque psoriasis, suggesting its role in everyday clinical use.
In this real-world study, deucravacitinib showed significant and sustained effectiveness, together with a favorable safety profile, in patients with moderate-to-severe plaque psoriasis. These findings support its role as an effective oral targeted therapy in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Ruggiero et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: